> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Samsara Sells 61,287 vTv Shares For Investors Who Redeemed Their Fund Interests
- URL: https://www.bullished.co/samsara-sells-61-287-vtv-shares-for-investors-who-redeemed-their-fund-interests-2375164a/
- Published: 2026-11-16T21:16:41.000Z
- Updated: 2026-11-16T21:16:41.000Z
- Description: The shares sold carried no economic interest for the fund's general partner or the managing member overseeing it.
- Author: Matteo Parrino
- Tags: SEC Filings, VTVT, Industry: Healthcare, Topic: Ownership & Activism

Samsara BioCapital sold [61,287 shares](https://www.sec.gov/Archives/edgar/data/0001699737/000169973726000024/xslSCHEDULE%5F13D%5FX01/primary%5Fdoc.xml?ref=bullished.co) of [vTv Therapeutics](https://www.bullished.co/tag/vtvt/), which develops oral treatments for metabolic and inflammatory diseases, Thursday at $17.60 each. The fund's amended SEC ownership disclosure filed Monday said the block sale was for limited partners who had redeemed their fund interests.

## Redeemed Investors Owned The Sale Proceeds

Neither Samsara BioCapital GP, the fund's general partner, nor Srinivas Akkaraju, its managing member, had an economic interest in the shares sold. Samsara held those shares solely for the benefit of the departing limited partners.

Akkaraju also manages Samsara Opportunity Fund GP, the general partner overseeing Samsara Opportunity Fund. His roles give him authority over voting and sales of the vTv securities held by both funds.

The ownership reporting relationship began on March 5, 2024\. Amendments followed on September 3, September 25 and December 9, 2025.

## Warrants Limit The Reported Stake

Akkaraju's reported beneficial ownership—the securities attributed to him through his control and applicable options—was [412,654 shares](https://www.sec.gov/Archives/edgar/data/0001699737/000169973726000024/xslSCHEDULE%5F13D%5FX01/primary%5Fdoc.xml?ref=bullished.co). The cover page listed 9.9%, rounded down because of filing-system field limits.

The percentages used 4,011,465 outstanding Class A shares as of November 5, 2026, plus applicable warrants and options exercisable within 60 days. Samsara BioCapital reported 247,069 shares, or 6.1%; Samsara Opportunity Fund reported 159,186, or 3.9%. Those interests overlap with the securities attributed to Akkaraju.

The funds directly held 187,443 and 106,000 common shares, respectively. They also held pre-funded and common warrants—rights to buy shares—whose terms prohibit exercises that would take ownership, including affiliates and other attribution parties, above 9.99%. That restriction currently limits the reporting persons to 412,654 shares of beneficial ownership. Akkaraju separately held 6,399 vested options or options scheduled to vest within 60 days.

## A Diabetes Pill Alongside Insulin

vTv's lead candidate, cadisegliatin, is being tested in a late-stage trial as a pill used alongside insulin for type 1 diabetes. The trial plans to enroll 150 patients.

A mid-stage type 2 diabetes trial began in the Middle East with partner G42 Investments funding it. vTv also has diabetes and inflammation candidates licensed to partners, including HPP737, whose global rights belong to Newsoara BioPharma. vTv is eligible for milestone payments and sales royalties under that license.

The Thursday sale concerned shares held for redeemed investors; the remaining reported ownership includes fund securities subject to the warrant exercise ceiling.

Learn

- [13D Filing Requirements And Deadline, Shown With Real Filings →](https://www.bullished.co/learn/13d-filing-requirements/)  
A Schedule 13D is required when you own more than 5% of a public company's voting shares. See the deadline, contents and real filings from this week.
- [13D Vs 13G: What Each 5% Stake Filing Means And How To Read One →](https://www.bullished.co/learn/13d-vs-13g/)  
13D vs 13G: both report stakes above 5%, but 13G is the short passive form and 13D explains intent. See real BlackRock and Pictet filings read in plain English.

### Sources

- [SCHEDULE 13D/A — Srinivas Akkaraju re: VTV THERAPEUTICS INC. (VTVT)](https://www.sec.gov/Archives/edgar/data/0001699737/000169973726000024/xslSCHEDULE%5F13D%5FX01/primary%5Fdoc.xml?ref=bullished.co) — SEC EDGAR

### More on vTv Therapeutics

- [vTv Therapeutics Has $77.2 Million In Cash As Diabetes Trial Heads Toward Results](https://www.bullished.co/vtv-therapeutics-has-77-2-million-in-cash-as-diabetes-trial-heads-toward-results-8f96b936/)
- [VTv Therapeutics Adds A Five-Day Proxy-Rule Check For Director Nominees In New Bylaws](https://www.bullished.co/vtv-therapeutics-adds-a-five-day-proxy-rule-check-for-director-nominees-in-new-bylaws-3c605669/)

[All vTv Therapeutics (VTVT) coverage →](https://www.bullished.co/tag/vtvt/)